Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levocap
- Development stage
- Unknown
- Lead developer
- Relmada Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Levocap is a branded generic version of levocetirizine, a second-generation H1-receptor antagonist. It is used for the symptomatic treatment of allergic rhinitis (including perennial allergic rhinitis) and chronic idiopathic urticaria. As the active R-enantiomer of cetirizine, it works by competing with histamine for H1-receptor sites on effector cells, thereby preventing the allergic response. It is developed and marketed by Panacea Pharmaceuticals, a generic pharmaceutical company based in Pakistan. The drug is typically formulated as an oral tablet and is known for its high selectivity and long duration of action with minimal sedative effects compared to first-generation antihistamines.
- Brand names
- Levocap
- Other names
- levocetirizinelevocetirizine dihydrochloride
02
Targets
HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Levocap.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Levocap.